Skip to content

Damora Therapeutics, Inc.

DMRA

CIK 0001800315 · Pharmaceutical Preparations · Nasdaq

  • Galecto, Inc. (until 2026-03-10)
  • Galecto Inc. (until 2020-10-28)
← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$36.89M
−878.8% YoY Q1 May 2026
EPS Diluted (TTM)
−$7.50
+121.5% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$38.3M
Q1 May 2026
Cash
$532.9M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
61.55M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings